Hcc2279

Human embryonic kidney 293T (HEK293T), Calu-3, and human NSCLC cell lines NCI-H23, NCI-H1703, NCI-H1793, NCI-H2009, NCI-H358, NCI-H460, NCI-H1299, NCI-H1437, HCC15, HCC827, and HCC2279 were purchased from Korean Cell Line Bank (Seoul, Korea) or KRIBB Cell Line Bank (Daejeon, Korea). Calu-3 and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium and all NSCLC cell lines in RPMI-1640 supplemented with 10% fetal bovine serum and penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were transfected with the indicated plasmids using TurboFect (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instructions and siRNAs (20–40 nM) by electroporation (Neon, Invitrogen) according to the manufacturer’s instructions. Cell viability was determined using the sulforhodamine B (SRB) assay, as previously described^{57 (link)}.

HCC2279 was obtained from the Korean Cell Line Bank, and H322 was obtained from the European Collection of Cell Cultures; all other cell lines were purchased from the American Type Culture Collection (ATCC). Using STR analysis, we were able to confirm the purity of all of the cell lines and ensure that they were true to type. The cells were cultured in accordance with protocols developed by the ATCC. We ordered talazoparib from Selleck and cetuximab from Merck. As we previously reported, we produced BsAb CT16 and PTJ12 in-house.